UroToday.com· @urotoday · X·· 1 天前评分70
正文 · 原文
Updated KEYNOTE-365 Cohort I Results: Pembrolizumab + Carboplatin/Etoposide vs Chemotherapy Alone for Neuroendocrine Prostate Cancer. Presented by Dr. Gunhild von Amsberg, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4ep7B7i #ProstateCancer #NEPC @myESMO
125 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org来源：UroToday.com · x.com